Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BHMT | Q93088 | 1/20 | 0.66 |
| ▸ | GLUL | P15104 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | OTC | P00480 | 1/20 | 0.56 |
| ▸ | GSR | P00390 | 1/20 | 0.54 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.53 |
| ▸ | GRM8 | O00222 | 1/20 | 0.53 |
| ▸ | GRM6 | O15303 | 1/20 | 0.53 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.53 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1662220 | 1.00 | BHMT (0.66) | BHMTGLULALDH1A1TDP1OTC | |
| SCHEMBL158652 | 1.00 | BHMT (0.66) | BHMTGLULALDH1A1TDP1OTC | |
| SCHEMBL1978027 | 0.94 | BHMT (0.69) | BHMTGLULTDP1OTCGSR | |
| SCHEMBL12648651 | 0.94 | BHMT (0.69) | BHMTGLULTDP1OTCGSR | |
| SCHEMBL13997086 | 0.94 | BHMT (0.69) | BHMTGLULTDP1OTCGSR | |
| Water SCHEMBL21747431 | 0.92 | BHMT (0.67) | BHMTGLULTDP1OTCGSR | |
| Hydrochloric Acid SCHEMBL21747394 | 0.92 | BHMT (0.67) | BHMTGLULTDP1OTCGSR | |
| SCHEMBL21747440 | 0.92 | BHMT (0.67) | BHMTGLULTDP1OTCGSR | |
| SCHEMBL21747426 | 0.92 | BHMT (0.67) | BHMTGLULTDP1OTCGSR | |
| Water SCHEMBL21747391 | 0.92 | BHMT (0.67) | BHMTGLULTDP1OTCGSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 752 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12589097-B2 | Apilimod compositions and methods of use | OrphAl Therapeutics Inc. (US) | 2026-03-31 | — | — | US | claimed |
| EP-4623932-A1 | AGENT FOR ALLEVIATING CLOZAPINE-INDUCED SIALORRHEA | National University Corporation Chiba University (JP) | 2025-10-01 | — | — | EP | claimed |
| CN-119639756-A | Application of kainate receptor Grik b in control of bactrocera dorsalis | 庐山市绿游生态农业开发有限公司 | 2025-03-18 | — | — | CN | claimed |
| CN-119639757-A | Application of rhodopsin receptor and inhibitor thereof in controlling bactrocera dorsalis | 庐山市绿游生态农业开发有限公司 | 2025-03-18 | — | — | CN | claimed |
| CN-119453115-A | Method for constructing epilepsy animal model and medicine obtained by screening epilepsy animal model and used for treating epilepsy | 中国科学院重庆绿色智能技术研究院 | 2025-02-18 | — | — | CN | claimed |
| WO-2025030033-A1 | APILIMOD COMPOSITIONS AND METHODS OF USE | ORPHAI THERAPEUTICS INC. (US) | 2025-02-06 | — | — | WO | claimed |
| EP-4475953-A1 | NMDAR ANTAGONISTS PREVENT AGEING AND AGING-ASSOCIATED CONDITIONS AND DISEASES THROUGH INCREASING 20S PROTEASOME ACTIVITY | SAHIN, Fikret (TR) | 2024-12-18 | — | — | EP | claimed |
| CN-119095622-A | NMDAR antagonists prevent aging and aging-related conditions and diseases by increasing 20S proteasome activity | 菲克雷特·萨欣 | 2024-12-06 | — | — | CN | claimed |
| WO-2024111636-A1 | AGENT FOR ALLEVIATING CLOZAPINE-INDUCED SIALORRHEA | 国立大学法人千葉大学 | 2024-05-30 | — | — | WO | claimed |
| US-11957688-B2 | Combination therapy with apilimod and glutamatergic agents | OrphAl Therapeutics Inc. (US) | 2024-04-16 | — | — | US | claimed |
| US-20140018395-A1 | Controlled Release Auris Sensory Cell Modulator Compositions and Methods for the Treatment of Otic Disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-01-16 | — | — | US | claimed |
| WO-2013138118-A1 | TREATMENT OF INFLAMMATORY DISORDERS IN NON-HUMAN MAMMALS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-09-19 | — | — | WO | claimed |
| US-8496957-B2 | Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders | OTONOMY, INC (US) | 2013-07-30 | — | — | US | claimed |
| CN-102614514-A | GLP-1 acceptor agonists used for treating pains | YONGXIANG WANG | 2012-08-01 | — | — | CN | claimed |
| US-8088150-B2 | Device for disc shunt implantation and peri-shunt injection | ALEEVA MEDICAL INC. (US) | 2012-01-03 | — | — | US | claimed |
| WO-2011028794-A2 | TREATMENT OF HUNTINGTON'S DISEASE WITH CYCLOSERINE AND AN NMDA RECEPTOR ANTAGONIST | LAZARUS THERAPEUTICS, INC. (US) | 2011-03-10 | — | — | WO | claimed |
| US-20090252786-A1 | Use of a Biologically Active Blood Serum for the Treatment of a Disorder Characterized in a Reduced Function of a GABA Receptor | OWEN HOLDING LTD. (GB) | 2009-10-08 | — | — | US | claimed |
| WO-2009121496-A2 | USE OF A BIOLOGICALLY ACTIVE BLOOD SERUM FOR THE TREATMENT OF A DISORDER CHARCTERIZED IN A REDUCED FUNCTION OF A GABA RECEPTOR | OWEN HOLDING LTD. (GB) | 2009-10-08 | — | — | WO | claimed |
| EP-2106799-A1 | Use of a biologically active blood serum for the treatment of a disorder characterized in a reduced function of a GABA receptor | OWEN Holding LTD (GB) | 2009-10-07 | — | — | EP | claimed |
| US-20090198248-A1 | Device for disc shunt implantation and peri-shunt injection | YEUNG JEFFREY E | 2009-08-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12589097-B2 | Apilimod compositions and methods of use | ZAP70, PIK3R4, PIKFYVE | BHMT 1790/4885GLUL 701/4885ALDH1A1 4573/4885 |
| US-20140018395-A1 | Controlled Release Auris Sensory Cell Modulator Compositions and Methods for the Treatment of Otic Disorders | OTC, MYOC, S100B | BHMT 4051/4885GLUL 1691/4885ALDH1A1 1154/4885 |
| US-11957688-B2 | Combination therapy with apilimod and glutamatergic agents | GRIK4, GRIN3A, GRIN2A | BHMT 918/4885GLUL 35/4885ALDH1A1 1760/4885 |
| US-20090252786-A1 | Use of a Biologically Active Blood Serum for the Treatment of a Disorder Characterized in a Reduced Function of a GABA Receptor | GABBR1, GABBR2, GABRA2 | BHMT 250/4885GLUL 155/4885ALDH1A1 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.